For $700M+, Vi­a­tris nabs two biotechs as eye dis­ease em­pha­sis comes in­to view

Vi­a­tris is con­tin­u­ing its plot to shift strate­gies, an­nounc­ing two ac­qui­si­tions Mon­day morn­ing in the wake of a re­port to sell off its Eu­ro­pean con­sumer health busi­ness.

The com­pa­ny, orig­i­nal­ly formed through the spin-out and merg­er of Pfiz­er’s My­lan and Up­john, will buy Oys­ter Point Phar­ma and Famy Life Sci­ences in deals val­ued be­tween $700 and $750 mil­lion. Oys­ter Point in­vestors will al­so re­ceive a CVR of up to $2 ex­tra per share, de­pend­ing on how its 2022 full-year re­sults pan out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER